Cargando…

Destabilizing RET in targeted treatment of thyroid cancers

Metastatic differentiated thyroid cancers (DTC) are resistant to traditional chemotherapy. Kinase inhibitors have shown promise in patients with progressive DTC, but dose-limiting toxicity is commonplace. HSP90 regulates protein degradation of several growth-mediating kinases such as RET, and we hyp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gild, M L, Bullock, M, Pon, C K, Robinson, B G, Clifton-Bligh, R J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674629/ https://www.ncbi.nlm.nih.gov/pubmed/26574568 http://dx.doi.org/10.1530/EC-15-0098

Ejemplares similares

Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects
por: Tsang, Venessa, et al.
Publicado: (2022)

Translational Utility of Liquid Biopsies in Thyroid Cancer Management
por: Wijewardene, Ayanthi A., et al.
Publicado: (2021)

Medullary Thyroid Cancer: Updates and Challenges
por: Gild, Matti L, et al.
Publicado: (2023)

Development of a novel clinical support tool for active surveillance of low risk papillary thyroid cancer
por: White, Eleanor, et al.
Publicado: (2023)

Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge
por: Gild, Matti L, et al.
Publicado: (2022)

Malignant struma ovarii with a robust response to radioactive iodine
por: Gild, M L, et al.
Publicado: (2020)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

Lobectomy and completion thyroidectomy rates increase after the 2015 American Thyroid Association Differentiated Thyroid Cancer Guidelines update
por: Worrall, Benjamin J, et al.
Publicado: (2023)

Clinical Activity of Selpercatinib in RET Mutant Pheochromocytoma-Case Reports
por: Konda, Bhavana, et al.
Publicado: (2021)

Thyroid Hormone Abuse Among Elite Athletes
por: Handelsman, David J, et al.
Publicado: (2023)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
por: Santoro, M., et al.
Publicado: (1993)

RF11 | PSAT370 I-PET Score: Combining Whole Body Iodine Scan and 18 Fluorodeoxyglucose Positron Emission Topography to Predict Progression in Thyroid Cancer
por: Wijewardene, Ayanthi, et al.
Publicado: (2022)

Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Infiltrative lymphocytic hypophysitis successfully treated with rituximab and mycophenolate mofetil
por: Lin, Mike, et al.
Publicado: (2020)

Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma
por: Kesby, Nicholas, et al.
Publicado: (2023)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

Allel RET+3 : T a medullary thyroid cancer
por: Pławski, A, et al.
Publicado: (2011)

On the RET Rearrangements in Chernobyl-Related Thyroid Cancer
por: Jargin, Sergei V.
Publicado: (2012)

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
por: Della Corte, C.M., et al.
Publicado: (2021)

Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET–rearranged thyroid cancer
por: Raman, Renuka, et al.
Publicado: (2022)

Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer
por: Wirth, Lori J., et al.
Publicado: (2019)

ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma
por: Luo, Jie, et al.
Publicado: (2019)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

RET kinase alterations in targeted cancer therapy
por: Liu, Xuan, et al.
Publicado: (2020)

A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours
por: Martínez-Aguilar, Juan, et al.
Publicado: (2015)

A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis
por: Fuchs, Talia L., et al.
Publicado: (2020)

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
por: Huang, Qin, et al.
Publicado: (2020)

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
por: Moura, M M, et al.
Publicado: (2009)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

Molecular Markers Guiding Thyroid Cancer Management
por: Nylén, Carolina, et al.
Publicado: (2020)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
por: Romei, Cristina, et al.
Publicado: (2018)

LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer
por: Lindquist, David, et al.
Publicado: (2018)

RET mutations in a large indian family with medullary thyroid carcinoma
por: Mahesh, D. M., et al.
Publicado: (2014)

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
por: Santoro, Massimo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_etnvicmp1pvbvgidk70vf0v8ap